A live webcast of ACADIA's presentation will be accessible on the company's website, www.acadia-pharm.com, under the investors section and an archived recording will be available on the website through November 9, 2009. About ACADIA Pharmaceuticals ACADIA is a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders. ACADIA's product candidates include pimavanserin in Phase III for Parkinson's disease psychosis in collaboration with Biovail, a product candidate in Phase II for chronic pain and a product candidate in Phase I for glaucoma, both in collaboration with Allergan, and AM-831 in IND-track development in collaboration with Meiji Seika Kaisha. All of the product candidates in ACADIA's pipeline emanate from discoveries made using its proprietary drug discovery platform. ACADIA maintains a website at www.acadia-pharm.com to which ACADIA regularly posts copies of its press releases as well as additional information and through which interested parties can subscribe to receive email alerts. SOURCE: ACADIA Pharmaceuticals Inc. ACADIA Pharmaceuticals Inc. Thomas H. Aasen, Vice President and Chief Financial Officer 858-558-2871 For full details on Acadia Pharmaceuticals (ACAD) click here. Acadia Pharmaceuticals (ACAD) has Short Term PowerRatings of 6. Details on Acadia Pharmaceuticals (ACAD) Short Term PowerRatings is available at This Link.
![]()
Email Print Archives Feedback Email Article Link
Close X
Related News [ACAD]
UPCOMING EVENTS
Learn new strategies, how to trade in this market, and the stocks you should be focusing on each day. Join us for our free 20 minute tele-seminars during the week.
Thursday December 3 12:30 PM
* Attendance is strictly limited and are filled on a first-come, first-served basis.
The TradingMarkets Directory
Stocks
Options
Forex
E-mini/Futures
How to Trade
Tools
PowerRatings
Blogs
|